Melola Discovery

← Melola Discovery

Journal SINTA 1

Effect of β-1,3-1,6-D-glukan (polysaccharide peptide) from miselia ganoderma lucidum extract as antioxidant and antiinflammation towards left ventricular systolic function in cardiometabolic patients

Heart Science Journal · Vol. 5 No. 4 (2024) · pp. 55–59

DOI
10.21776/ub.hsj.2024.005.04.9
ISSN
2721-9984, 2721-9976
Published
2024-10-28
Publisher
Universitas Brawijaya
Language
en

Abstract

Background: Cardiometabolic disease (CMD) describes a metabolic condition often associated with cardiovascular disease. It has been revealed that the Ganoderma lucidum polysaccharide peptide (GLPP) possesses anti-inflammatory and antioxidant qualities. Objective: This study aimed to find out how GLPP affected oxidative stress, inflammation, and left ventricular function in individuals with cardiometabolic syndrome.Methods: A multicenter double-blinded randomized controlled trial was carried out. Subjects with cardiometabolic syndrome received either GLPP or a placebo for ninety days. Before taking the initial treatment and one day following the last treatment intake, blood samples were taken from every participant. The enzyme-linked immunosorbent assay was used to evaluate the levels of serum tumor necrosis factor (TNF)-α, interleukin-6 (IL-6), malondialdehyde (MDA), and high-sensitivity-C-Reactive Protein (hs-CRP) while the colorimetric test was used to measure the levels of superoxide dismutase (SOD). Global longitudinal strain (GLS) and Left ventricle ejection fraction (LVEF) were measured by single echocardiographer expert validation.Results: The MDA level was decreased in the GLPP treatment group (mean 56.0 ± 71.4 ng/mL to 27.7 ± 12.0 ng/mL, p= 0.023) compared to the control group (mean 39.3 ± 29.2 ng/mL to 38.3 ± 17.7 ng/mL, p= 0.719). However, the SOD level remained constant in the GLPP treatment (mean 122.2 ± 176.1 U/mL to 93.0 ± 40.9 U/mL, p=0.925) instead of significantly declining in the control group (mean 102.0 ± 67.3 U/mL to 64.0 ± 52.0 U/mL, p=0.016). The marker of TNF-α and hsCRP were significantly decreased in all groups (both p 0.05).Conclusion: Patients with cardiometabolic syndrome may benefit from GLPP treatment for 90 days in terms of reduced inflammation, oxidative stress, and improved systolic left ventricular performance.

Keywords

Collaboration network of the authors

40 authors · 271 co-authorship links · showing the 40 most connected

Hover or tap a name to highlight its co-authors. Double-click to open the author's page.

  • University of Brawijaya
  • Affiliation unknown
  • Different organisations
  • Same organisation
  • Affiliation unknown
  • Thicker line = more joint articles · bigger circle = more articles
Show as table
Co-authorOrganisationJoint articles
Mohammad Saifur RohmanAffiliation unknown28
Cholid Tri TjahjonoAffiliation unknown20
Ardian RizalAffiliation unknown19
Novi KurnianingsihAffiliation unknown18
Budi SatrijoAffiliation unknown16
Indra PrasetyaAffiliation unknown14
Setyasih AnjarwaniAffiliation unknown13
Heny MartiniAffiliation unknown12
Sasmojo WiditoAffiliation unknown8
Wella KarolinaAffiliation unknown7
Yoga WaranugrahaAffiliation unknown5
Nikhen NoverikeAffiliation unknown4
Valerinna YogibuanaAffiliation unknown4
Lukitasari Ayu GaluhAffiliation unknown4
Putri Annisa KamilaUniversity of Brawijaya4
Imelda KrisnasariAffiliation unknown3
Ayu Asri Devi AdityawatiAffiliation unknown3
Muhammad Rizki FadlanAffiliation unknown3
Veny KurniawatiAffiliation unknown2
Dadang HendrawanAffiliation unknown2
Tri AstiawatiAffiliation unknown2
Valerinna Yogibuana Swastika PutriAffiliation unknown2
Nur Kaputrin DwigustiningrumAffiliation unknown2
Lutfi Hafiz ZunardiAffiliation unknown2
Olivia HandayaniAffiliation unknown2
Liemena Harold AdrianAffiliation unknown2
Ratna PancasariAffiliation unknown2
Krishna Ari NugrahaAffiliation unknown2
Imam Mi'raj SuprayogaAffiliation unknown2
Titin A WihastutiAffiliation unknown1
Achdiat AgoesAffiliation unknown1
Satuman SatumanAffiliation unknown1
Teuku HeriansyahAffiliation unknown1
Yoseph Budi UtomoAffiliation unknown1
Mohammad Ryan RamadhanAffiliation unknown1
Taufieq Ridlo MakhmudAffiliation unknown1
Renny SuwarniatyAffiliation unknown1

Affiliations come from OpenAlex; journal OAI-PMH metadata carries none. Authors without an OpenAlex ID are matched by name, which can merge or split people.

Metadata source: OAI-PMH (metadata jurnal) https://heartscience.ub.ac.id/index.php/heartscience/oai, first harvested 8 Nov 2026, last seen 8 Nov 2026.
Original metadata (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Effect of β-1,3-1,6-D-glukan (polysaccharide peptide) from miselia ganoderma lucidum extract as antioxidant and antiinflammation towards left ventricular systolic function in cardiometabolic patients</dc:title>
	<dc:creator xml:lang="en">Aryanugraha, Teguh</dc:creator>
	<dc:creator xml:lang="en">Sargowo, Djanggan</dc:creator>
	<dc:creator xml:lang="en">Rahimah, Anna Fuji</dc:creator>
	<dc:subject xml:lang="en">oxidative stress</dc:subject>
	<dc:subject xml:lang="en">inflammation</dc:subject>
	<dc:subject xml:lang="en">cardiometabolic syndrome</dc:subject>
	<dc:subject xml:lang="en">echocardiography</dc:subject>
	<dc:subject xml:lang="en">Ganoderma lucidum</dc:subject>
	<dc:description xml:lang="en">Background: Cardiometabolic disease (CMD) describes a metabolic condition often associated with cardiovascular disease. It has been revealed that the Ganoderma lucidum polysaccharide peptide (GLPP) possesses anti-inflammatory and antioxidant qualities. Objective: This study aimed to find out how GLPP affected oxidative stress, inflammation, and left ventricular function in individuals with cardiometabolic syndrome.Methods: A multicenter double-blinded randomized controlled trial was carried out. Subjects with cardiometabolic syndrome received either GLPP or a placebo for ninety days. Before taking the initial treatment and one day following the last treatment intake, blood samples were taken from every participant. The enzyme-linked immunosorbent assay was used to evaluate the levels of serum tumor necrosis factor (TNF)-α, interleukin-6 (IL-6), malondialdehyde (MDA), and high-sensitivity-C-Reactive Protein (hs-CRP) while the colorimetric test was used to measure the levels of superoxide dismutase (SOD). Global longitudinal strain (GLS)  and Left ventricle ejection fraction (LVEF) were measured by single echocardiographer expert validation.Results: The MDA level was decreased in the GLPP treatment group (mean 56.0 ± 71.4 ng/mL to 27.7 ± 12.0 ng/mL, p= 0.023) compared to the control group (mean 39.3 ± 29.2 ng/mL to 38.3 ± 17.7 ng/mL, p= 0.719). However, the SOD level remained constant in the GLPP treatment (mean 122.2 ± 176.1 U/mL to 93.0 ± 40.9 U/mL, p=0.925) instead of significantly declining in the control group (mean 102.0 ± 67.3 U/mL to 64.0 ± 52.0 U/mL, p=0.016). The marker of TNF-α and hsCRP were significantly decreased in all groups (both p&amp;lt;0.05), but IL-6 was only significantly decreased in the control group (mean 1149.3 ± 581.7 pg/mL to 744.8 ± 336.5 pg/mL, p=0.010). The GLS was significantly decreased in the GLPP treatment group (-16.1 ± 4.1 to -17.5 ± 4.8, p=0.048) but there was no difference in LVEF in both groups (p&amp;gt;0.05).Conclusion: Patients with cardiometabolic syndrome may benefit from GLPP treatment for 90 days in terms of reduced inflammation, oxidative stress, and improved systolic left ventricular performance.</dc:description>
	<dc:publisher xml:lang="en">Universitas Brawijaya</dc:publisher>
	<dc:date>2024-10-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://heartscience.ub.ac.id/index.php/heartscience/article/view/15768</dc:identifier>
	<dc:identifier>10.21776/ub.hsj.2024.005.04.9</dc:identifier>
	<dc:source xml:lang="en">Heart Science Journal; Vol. 5 No. 4 (2024): The Current Perspective About Cardiometabolic Disease; 55-59</dc:source>
	<dc:source>2721-9984</dc:source>
	<dc:source>2721-9976</dc:source>
	<dc:source>10.21776/ub.hsj.2024.005.04</dc:source>
	<dc:language>en</dc:language>
	<dc:relation>https://heartscience.ub.ac.id/index.php/heartscience/article/view/15768/457</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Teguh Aryanugraha</dc:rights>
</oai_dc:dc>